Xiamen Amoytop Biotech Co., Ltd.
SSE:688278.SS
73.64 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,817.158 | 2,100.323 | 1,526.905 | 1,132.228 | 793.934 | 729.666 | 448.283 | 323.081 | 280.371 |
| Cost of Revenue
| 183.511 | 143.159 | 169.239 | 125.134 | 83.649 | 79.974 | 55.938 | 41.678 | 30.743 |
| Gross Profit
| 2,633.647 | 1,957.164 | 1,357.666 | 1,007.094 | 710.285 | 649.693 | 392.345 | 281.403 | 249.627 |
| Gross Profit Ratio
| 0.935 | 0.932 | 0.889 | 0.889 | 0.895 | 0.89 | 0.875 | 0.871 | 0.89 |
| Reseach & Development Expenses
| 287.978 | 221.36 | 149.836 | 81.507 | 76.675 | 53.406 | 40.607 | 18.903 | 8.933 |
| General & Administrative Expenses
| 76.733 | 210.309 | 33.316 | 22.881 | 18.174 | 16.603 | 12.349 | 50.641 | 47.613 |
| Selling & Marketing Expenses
| 749.549 | 846.607 | 703.148 | 597.556 | 428.676 | 419.684 | 266.514 | 203.365 | 153.097 |
| SG&A
| 826.283 | 1,057.81 | 736.464 | 620.437 | 446.85 | 436.287 | 278.863 | 254.007 | 200.709 |
| Other Expenses
| 541.921 | -1.482 | 73.242 | 65.408 | 33.13 | 33.169 | -25.931 | -8.684 | -2.095 |
| Operating Expenses
| 1,662.911 | 1,276.443 | 959.542 | 767.352 | 556.655 | 522.861 | 350.538 | 263.002 | 210.938 |
| Operating Income
| 970.737 | 680.72 | 406.924 | 248.528 | 158.14 | 116.067 | 34.718 | 10.046 | 29.971 |
| Operating Income Ratio
| 0.345 | 0.324 | 0.267 | 0.22 | 0.199 | 0.159 | 0.077 | 0.031 | 0.107 |
| Total Other Income Expenses Net
| -39.71 | -40.066 | -50.998 | -33.242 | -19.073 | -25.055 | -20.443 | -2.377 | 2.893 |
| Income Before Tax
| 931.027 | 640.654 | 355.926 | 215.286 | 139.067 | 91.013 | 14.275 | 7.669 | 32.865 |
| Income Before Tax Ratio
| 0.33 | 0.305 | 0.233 | 0.19 | 0.175 | 0.125 | 0.032 | 0.024 | 0.117 |
| Income Tax Expense
| 103.424 | 85.205 | 68.906 | 34.085 | 22.498 | 26.719 | -1.728 | 2.501 | 3.551 |
| Net Income
| 827.602 | 555.449 | 287.02 | 181.201 | 116.57 | 64.294 | 16.003 | 5.169 | 29.314 |
| Net Income Ratio
| 0.294 | 0.264 | 0.188 | 0.16 | 0.147 | 0.088 | 0.036 | 0.016 | 0.105 |
| EPS
| 2.03 | 1.37 | 0.71 | 0.45 | 0.29 | 0.16 | 0.04 | 0.01 | 0.09 |
| EPS Diluted
| 2.03 | 1.37 | 0.71 | 0.45 | 0.29 | 0.16 | 0.04 | 0.01 | 0.09 |
| EBITDA
| 1,006.842 | 699.854 | 404.621 | 260.904 | 179.698 | 135.09 | 68.125 | 40.738 | 56.504 |
| EBITDA Ratio
| 0.357 | 0.333 | 0.265 | 0.23 | 0.226 | 0.185 | 0.152 | 0.126 | 0.202 |